Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome

Stéphane Auvin1,2,*, Blandine Dozières-Puyravel1,2,*, Andreja Avbersek3, David Sciberras3, Jo Collier3, Karine Leclercq3, Pavel Mares4, Rafal M. Kaminski3 & Pierandrea Muglia3,5

1Service de Neurologie Pédiatrique, Hôpital Robert Debré, Paris, France
2Université de Paris, INSERM U1141, F-75019, Paris, France
3UCB Pharma, Braine-l’Alleud, Belgium
4Institute of Physiology, The Czech Academy of Sciences, Prague, Czech Republic

Abstract

Objective: Infantile spasm syndrome (ISS) is an epileptic encephalopathy without established treatment after the failure to standard of care based on steroids and vigabatrin. Converging lines of evidence indicating a role of NR2B subunits of the N-methyl-D-aspartate (NMDA) receptor on the onset of spasms in ISS patients, prompted us to test radiprodil, a negative allosteric NR2B modulator in preclinical seizure models and in infants with ISS. Methods: Radiprodil has been tested in three models, including pentylenetetrazole-induced seizures in rats across different postnatal (PN) ages. Three infants with ISS have been included in a phase 1b escalating repeated dose study. Results: Radiprodil showed the largest protective seizure effects in juvenile rats (maximum at PN12, corresponding to late infancy in humans). Three infants resistant to a combination of vigabatrin and prednisolone received individually titrated doses of radiprodil for up to 34 days. Radiprodil was safe and well tolerated in all three infants, and showed the expected pharmacokinetic profile. One infant became spasm-free and two showed clinical improvement without reaching spasm-freedom. After radiprodil withdrawal, the one infant continued to be spasm-free, while the two others experienced seizure worsening requiring the use of the ketogenic diet and other antiepileptic drugs. Interpretation: Radiprodil showed prominent anti-seizure effect in juvenile animals, consistent with the prevalent expression of NR2B subunit of the NMDA receptor at this age in both rodents and humans. The clinical testing, although preliminary, showed that radiprodil is associated with a good safety and pharmacokinetic profile, and with the potential to control epileptic spasms.

Introduction

Infantile Spasms Syndrome (ISS) is an infantile epileptic encephalopathy. It is characterized by epileptic spasms occurring around 6 months of age and most frequently severe abnormal interictal electroencephalographic (EEG) activity, showing hypsarrhythmia or a similar pattern.1,2 The etiology of ISS is diverse. The most frequently encountered etiologies are hypoxic-ischemic encephalopathy, chromosomal abnormalities, monogenic conditions such as tuberous sclerosis complex, and brain malformations. There is substantial genetic heterogeneity in the ISS population with causative pathogenic variants involving more than 30 different genes,3 as recently illustrated in a study of 92 patients with ISS.4 However, in up to 40% of cases, the cause remains unidentified.5–7 Irrespective of the genetic etiology, converging lines of evidence suggest a pathogenetic role of glutamate-N-methyl-D-aspartate (NMDA) transmission in ISS.8,9 The incidence of ISS is 0.16–0.42 per 1000 live births.10 The prevalence is estimated to be 1–9/100,000, fulfilling the criteria for an orphan disease. Nevertheless, ISS is the
single largest epilepsy syndrome in the infantile period. Onset of spasms is often associated with developmental arrest or regression. The primary goal of treatment is to stop the spasms early in the course of the disease in order to minimize the developmental delay. Up to 20% of patients fail to respond to current standard of care (SoC) with hormonal therapy, vigabatrin, or their combination.

The SoC treatments with proven efficacy include hormonal treatments (ACTH, tetracosactide, or prednisolone) and vigabatrin. Vigabatrin was the first drug approved for the treatment of ISS by the FDA. Although ACTH has been used in infantile spasms since the first description of its efficacy in 1958, approval by the FDA was obtained in 2010.

Infants who fail to respond to SoC represent the drug-resistant ISS population for which no established treatment is available. In those infants there is a clear unmet need for an efficacious treatment that will halt spasms and related EEG abnormalities. Furthermore, such an efficacious treatment may eventually provide additional benefits to the entire ISS population as a safer alternative to the current standard of care.

The NR2B subunit of NMDA receptor is a relevant target for early onset epilepsy: rationale for potential therapeutic use of radiprodil

N-methyl-D-aspartate is one of the main excitatory glutamate receptors mediating a number of CNS functions including normal brain development and activity-dependent synaptic plasticity. NMDA receptor dysfunction is also implicated in a range of neuropsychiatric disorders including epilepsy. NMDA receptor antagonists have been shown to have antiepileptic effects including anecdotal reports of memantine use in epilepticencephalopathies. Converging lines of evidence suggest the NMDA receptor is involved in the disrupted electrical activity and generation of seizures observed in ISS. Activation of NMDA induces spasm-like seizures in rat pups, and systemic administration of NMDA is used as an ISS animal model characterized by interictal large amplitude asynchronous EEG abnormalities. During the first year of life in human, and during the corresponding age in rat pups, the composition of the NMDA receptor is prevalently constituted by the NR2B subunit. The increased neural excitability during early development, coinciding with the typical onset time of ISS, may be at least partially mediated by an increased expression of NR2B-containing NMDA receptors. Indeed, NR2B-selective compounds, such as ifenprodil, showed an age-dependent anticonvulsant effect in rodents, which appears consistent with the increased expression of NR2B containing receptors early in the development. More recently, de novo gain of function mutations of the GRIN2B gene, coding for the NR2B subunit, have been reported as a rare cause of ISS. It could be then hypothesized that the NR2B subunit is a therapeutic target for ISS, and that compounds inhibiting its activity have the potential to suppress spasms.

Radiprodil is an orally active, negative allosteric modulator of NR2B receptors. Interestingly, in vitro electrophysiological studies indicate that radiprodil fully retains its pharmacological profile in human NMDA receptors expressing the aforementioned NR2B gain of function mutations associated with ISS, while other nonselective NMDA receptor antagonists lose their potency. Consequently, radiprodil could be a candidate drug with the potential for controlling spasms. Radiprodil was initially developed as a treatment for neuropathic pain. The clinical experience with radiprodil was obtained in 460 adult individuals, including healthy volunteers in the phase 1 program and 332 patients with neuropathic pain. Development in neuropathic pain was terminated due to lack of efficacy, however these studies established a well-tolerated exposure range in adults which supported the dose selection for the ISS study. To enable pediatric development, a juvenile toxicology study in rat pups was conducted, and the pediatric oral formulation was developed. Bioequivalence of the pediatric formulation was demonstrated (NCT02647697), and a microsampling technique for facilitating PK sampling in infant was validated.

Here, we report the results of the in vivo preclinical studies in rodents, and the observed effects of radiprodil in three infants with ISS exposed in an open-label phase 1b study with three individually titrated escalating doses of radiprodil administered for up to 34 days.

Radiprodil: Preclinical Data

The anticonvulsant effects of radiprodil were assessed in two standard models of generalized and focal seizures in adult mice. In the audiogenic seizure model, radiprodil displayed very potent, dose-dependent protective activity against generalized clonic convulsions, which are the key efficacy endpoint in this model. The obtained 50% effective dose (ED50) value was equal to 2.1 mg/kg (Fig. 1A). In contrast, radiprodil (up to 30 mg/kg) did not display any significant activity against focal seizures induced by electrical stimulation with 6 Hz current at 44 mA (data not shown).

The anticonvulsant activity of radiprodil was also tested in male Wistar rats at different PN ages, that is, PN7, PN12, and PN70, using pentylenetetrazole (PTZ) as a convulsant which typically induces generalized tonic-clonic seizures in all age groups. Radiprodil showed dose-
dependent protective effects against the tonic phase of generalized seizures only in PN7 and PN12, while it did not have any significant anticonvulsant activity in PN70 rats injected with PTZ (Fig. 1B). The highest potency of radiprodil was observed in PN12 rats, approximately corresponding to infantile-early childhood in humans. At 3 mg/kg radiprodil showed a statistically significant protective effect against the tonic phase of PTZ-induced convulsions, while at 10 mg/kg it completely abolished tonic seizures in PN12 rats.

Radiprodil: Clinical Results of Phase 1b Testing in ISS Patients

The clinical study was a phase 1b, open label, ascending dose adaptively designed study (NCT02829827).

The first two participants were enrolled as sentinel subjects before the inclusion of any additional infants. The aim was to include 10 participants in the first part of the study until an interim analysis, but the study was stopped earlier because of the challenge in recruiting patients meeting all inclusion and exclusion criteria.

1 The inclusion criteria were as follows:
   - infant between 2 and 14 months of age with a diagnosis of ISS.
   - The diagnosis requirement included both confirmation of the clinical features of ISS and evidence of hypsarrhythmia or other disordered interictal patterns consistent with the diagnosis of ISS on 4-h video-EEG.
   - failure to respond to SoC defined as continuing spasms despite treatment with vigabatrin and one of the hormonal treatments (including ACTH, tetracosactide, and prednisolone), given in combination or sequentially for a minimum of 14 days.

2 The exclusion criteria were as follows:
   - a diagnosis of ISS more than 6 months before screening
   - a structural brain abnormality that likely required surgery during the study
   - a clinically significant abnormality on electrocardiogram

Figure 1. Anticonvulsant effects of radiprodil in rodent seizure models. (A) Dose-dependent protection against generalized clonic convulsions in the mouse audiogenic seizure model. (B) Age-dependent protection against generalized tonic seizures in the rat pentyleneterazol (PTZ) model at three different postnatal (PN) periods.
- any previous or ongoing medical condition that could have significantly interfered with the safety, tolerability and/or absorption, metabolism, and excretion of the study drug.

**Study drug**

Radiprodil was supplied as granules in bottles for oral suspension. The granules were reconstituted as a suspension prepared extemporaneously by adding 40 mL of diluent. Three dose levels of radiprodil were administered b.i.d.: 0.04 mg/kg (Low), 0.10 mg/kg (Medium), and 0.21 mg/kg (High).

**Rationale for dose selection**

The selection of the first lower dose and the upper dose limit was determined using available data from previous clinical experience with radiprodil and based on a number of considerations on the known NR2B pharmacology. First, safety considerations were based on the observation that 30 mg single or multiple dose were considered safe and well tolerated in adults also after long-term (14-week) treatment. The drug exposure associated with 30 mg was expected to achieve a maximum of 80% NR2B occupancy, that is below the uneventful drug concentration achieved in the juvenile toxicology dose (projected to achieve ~95% NR2B occupancy). Second, the lower drug concentration associated with anti-seizure efficacy in the preclinical rat pup PTZ model was observed with 60% NR2B occupancy, and the expected NR2B receptor occupancy associated with a dose of felbamate, that has affinity for NR2B, and is effective in ISS is around 30%.

Third, a physiologically based pharmacokinetic (PBPK) model, derived from the data in two clinical pharmacology studies mentioned above and its adaptation for pediatric simulations was used to establish doses that would be expected to produce the desired concentrations in infants. Simcyp Population-Based Simulator (v. 15.1) was used for all simulations. The starting dose of 0.04 mg/kg was selected as being safe and expected to produce NR2B occupancy of approximately 20%, 28-fold lower than the no-observed-adverse-effect level (NOAEL) exposure in the juvenile rat toxicology study (100 mg/kg/day), and four times lower than the 30 mg of radiprodil in adult subjects considered safe and well tolerated. The high dose was capped at drug concentrations expected to achieve 60% NR2B occupancy which was judged to be the limit of a positive benefit/risk ratio.

**Study design**

The study was approved by the ethic review board and by the French competent authority (Agence Nationale de Sécurité du Médicament et des Produits de Santé). After obtaining informed consent from the parents or caregivers, each participant underwent a baseline evaluation including a 4-h video-EEG.

Study participants were eligible to enter the study if they continued to have spasms despite treatment with vigabatrin and one of the hormonal treatments, given in combination or sequentially for a minimum of 14 days. Participants taking hormonal treatments at the time of enrollment had their treatment discontinued in a tapered fashion. Participants taking vigabatrin continued on a stable dose. It was recommended that any other antiepileptic drugs for non-ISS seizures should have been given on a stable regimen during the radiprodil treatment period.

The radiprodil treatment period consisted of the titration, maintenance, and tapering periods. Following the baseline evaluation, each study participant entered an individualized dose titration schedule. The titration included three dose levels of radiprodil: 0.04 mg/kg (low), 0.10 mg/kg (medium), and 0.21 mg/kg (high dose) given twice daily (bid) for 3 days (Fig. 2).

The decision on whether to increase the dose was made in the morning on the day following the third day of a specific dose level, based on the effect on spasms (clinical and 1-h video-EEG on the previous day) and if there were any safety/tolerability issues. The decisions were taken during a Safety Review Meeting between the study team and the investigators. If no spasms occurred in the 24-h period from 7 AM Day 3 to 7 AM Day 4 b.i.d. dosing was continued at the current dose level as the maintenance dose. For study participants whose doses were titrated to the high dose, if the spasms were still present on Day 3 of the high dose, the high dose was maintained and spasms were reassessed on Day 14. If spasms were still present on Day 14, radiprodil was tapered and then discontinued. For study participants who were spasm-free on Day 14, the radiprodil dosing was continued until Day 28; following Day 28, it was tapered and discontinued.

**Clinical Results**

Three participants were included and treated with radiprodil, entered into the maintenance period, and completed the treatment period. All three participants received all scheduled doses, plasma exposure both in terms of C_{max} and AUC_{(0-t)} increased with dose in a linear fashion (Table 1) as expected based on the PKPB modeling (Fig. 3).

- Study participant #1 was male, 11 months old at screening. He was 10 months old at diagnosis of ISS due to a malformation of cortical development (right insular polymicrogyria).
Study participant #2 was female, 5 months old at screening. She was 4 months old at diagnosis of ISS of unknown underlying etiology. She had a clinically significantly neurological history (abnormal periventricular white matter on MRI, pyramidal and extrapyramidal disorder, and developmental delay).

Study participant #3 was male, 7 months old at screening. He was 5 months old at diagnosis of ISS and had initially an unknown underlying etiology but was later diagnosed with a large malformation of cortical development.

All included patients had abnormal development prior to/after the onset of ISS, had a normal metabolic screening test, and took a wide range of prior anticonvulsants (Table 2). No clinically significant changes from baseline in vital signs or physical measurements were observed during the overall treatment period with radiprodil. The duration of exposure to radiprodil ranged from 26 to 34 days.

Patient #1 became seizure free with the medium dose, and remained seizure free after the discontinuation of radiprodil up to and including the final study visit at 18 months. Patient #2 and #3 had a clinical improvement with a decrease of epileptic spasms from several daily clusters of spasms lasting for several minutes to isolated epileptic spasms one to three times a day with the high dose of radiprodil. This improvement remained stable for the two patients over the maintenance period. Both patients experienced recurrence of the clusters of spasms when radiprodil was withdrawn. The interictal EEG recordings for each patient were similar at baseline and at the end of the maintenance period (Fig. 4).

All three study participants experienced a total of 20 Treatment Emergent Adverse Events (TEAEs) during the study. The most common nonserious TEAEs (occurring in >1 study participant) were vomiting (n = 2 events in two participants) and pyrexia (n = 4 events in two participants). No study participants discontinued the study due to TEAEs or experienced any drug-related TEAEs.

The study was terminated due to insufficient enrollment. To date, after 10–11 months after the treatment with radiprodil, the study participant #1 remains seizure free. After an initial relapse of spasms following radiprodil discontinuation, the two other infants eventually became spasm-free after few months with a combination of AEDs and the use of the ketogenic diet (Table 2).

Table 1. Pharmacokinetic parameters.

| Study participant | Dose (mg/kg) | AUC (0–t) (ng/mL·h) | Cmax (ng/mL) | Cmin (ng/mL) | tmax (h) (median) | t1/2 (h) |
|------------------|--------------|---------------------|-------------|-------------|------------------|--------|
| Patient #1       |              |                     |             |             |                  |        |
| Day 2L           | 0.04         | 214                 | 47.1        | 7.5         | 1.25             | 6.7    |
| Day 7Maint       | 0.1          | 535                 | 113.8       | 18.9        | 1.69             | 6.8    |
| Day 14Maint      | 0.1          | 535                 | 113.7       | 18.9        | 1.69             | 6.7    |
| Patient #2       |              |                     |             |             |                  |        |
| Day 2L           | 0.04         | 185                 | 44.3        | 5.28        | 1.15             | 5.3    |
| Day 8Maint       | 0.21         | 462                 | 107.2       | 13.9        | 1.4              | 5.3    |
| Day 14Maint      | 0.21         | 969                 | 208.4       | 30.0        | 1.85             | 5.3    |
| Patient #3       |              |                     |             |             |                  |        |
| Day 2L           | 0.04         | 198                 | 45.8        | 6.3         | 1.2              | 5.9    |
| Day 7Maint       | 0.21         | 495                 | 110.3       | 16.0        | 1.5              | 5.9    |
| Day 14Maint      | 0.21         | 1036                | 207.8       | 34.7        | 1.9              | 5.9    |

PK parameters were derived from a pop-PK model. 
Tmax was the median.
L, radiprodil low dose that is, 0.04 mg/kg; Maint, maintenance; PK, pharmacokinetic; SS, Safety Set.
Discussion

Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptors. We report here the preclinical and first clinical data in infants obtained with this compound. Radiprodil exerted anticonvulsant efficacy with a high potency in an animal model of generalized clonic seizures. Interestingly, radiprodil displayed much stronger anticonvulsant effect in young rat pups than in adult animals.

The age-dependent anticonvulsant effect of radiprodil was consistent with data obtained with another NR2B-selective compound, ifenprodil.\textsuperscript{22,23} The higher efficacy of radiprodil at that specific developmental age is likely to be explained by the developmental changes in expression of NR2B-containing NMDA receptors, which predominate in the developing brain and are progressively outnumbered by NR2A-containing NMDA receptors during adulthood. This developmental pattern of NR2B expression of the NMDA receptors is conserved across species, including humans.\textsuperscript{30–32} This lead to hypothesize a specific and stronger seizure protective effect of radiprodil in infants.

Infantile spasm syndrome is the most frequent infantile epileptic syndrome despite its low incidence. There is no wide consensus for the treatment of ISS, although SoC is based on hormonal therapy (ACTH or prednisolone) and vigabatrin. Although steroids and vigabatrin used as monotherapy or in combination show good level of efficacy for the majority of patients, ISS remains a therapeutic challenge associated with a significant patient burden that include high level of intellectual disability and high risk of developing other types of pharmacoresistant seizures. There are limited data providing evidence for the selection of the third or later lines of treatments. Accumulating prospective and retrospective studies suggest the ketogenic diet is beneficial, while conventional antiepileptic drugs do not provide significant seizure reduction.\textsuperscript{33} Felbamate is an antiepileptic drug that interferes with NMDA receptors by blocking the NR1A and NR2B subunits and also acts by blockage of the voltage-gated sodium channels, potentiation of GABA receptor currents,
and inhibition of voltage-gated calcium currents.\textsuperscript{34,35} In our center, we recently reported that 28\% of patients became spasm-free with felbamate at a mean daily dose of 34.6 mg/kg after failure of at least three treatments (vigabatrin, steroids and also for most of them the ketogenic diet).\textsuperscript{29} Until recently very few ISS patients have been reported as successfully treated by felbamate (\(n = 15\)).\textsuperscript{36,37} A 72\% median reduction of spasms on felbamate compared to baseline was reported in 11 patients using 2-h video-EEG recordings as a primary endpoint.\textsuperscript{37} These clinical data contribute to the hypothesis that modulation of NMDA receptors, and radiprodil can have a therapeutic role for ISS.

The phase 1b clinical study (NCT02829827) reported here, involved several centers in Europe. The study, however, was terminated because of the challenge in recruiting a sufficient number of patients within a reasonable time frame. Among the three infants enrolled to the study, one patient became spasm-free, and two patients had clinical improvement followed by a worsening after radiprodil discontinuation. This first clinical use of radiprodil in infants indicates the compound was generally well tolerated. There were no treatment-related serious adverse events, no sedation, and no behavioral changes observed. In all three patients, the pharmacokinetic data were closely consistent with the predicted exposures from the PBPK modeling.

A number of factors contributed to the difficulty in recruiting infants into the study. For safety purposes, the design of the study required that the first two infants treated by radiprodil remained admitted to the in-patient department for about 2 months. This was a limitation for most of the centers and an extra burden for families. In addition to the low incidence of the syndrome, the more recent use of a combination of vigabatrin and oral steroids therapy has, most likely, further decreased the number of infants meeting the selection criteria. Indeed, 72\% of the infants are spasm-free after treatment with ACTH and vigabatrin combination.\textsuperscript{15}

Targeting NR2B subunit of the NMDA receptors appears to be a promising therapeutic strategy based on the receptor neurobiology coinciding with the onset of seizures, its predominant expression in infancy, the initial experimental evidence of radiprodil reported in the

### Table 2. Individual efficacy responses.

| Included patients | Patient #1 | Patient #2 | Patient #3 |
|-------------------|------------|------------|------------|
| **Maintenance dose** | Medium | High | High |
| **Underlying cause of ISS** | MCD | Unknown | Unknown MCD found after the study |
| **Previous AED** | VPA, LTG, LVT | VGB 130 mg/kg/d, prednisolone 10 mg/d | VGB 146 mg/kg/d, prednisolone 20 mg/d |
| **AED at inclusion** | VPA 26 mg/kg/d, LTG 1.7 mg/kg/d, VGB 130 mg/kg/d, Prednisolone 10 mg/d | | |
| **Clinical responder** | Y | N | N |
| **Electroclinical responder** | Y | N | N |
| **Time to cessation of spasms for clinical responders (days)** | 6 | NA | NA |
| **Interictal EEG at Baseline** | Slow waves | Hypsarrhythmia | Fragmented |
| **Interictal EEG at the end of the maintenance period** | No change | No change | No change |
| **Extended clinical responder** | Y | NA | NA |
| **Extended electroclinical responder** | Y | NA | NA |
| **Clinical relapse** | N | NA | NA |
| **Clinical worsening with radiprodil withdrawal** | NA | Y | Y |
| **Time after inclusion** | M11 | M10 | M10 |
| **Clinical follow-up** | Spasm-free | Spasms-free | Spasms-free |
| **AEDs** | VPA, LTG | FLB, KD | VPA, LTG, FLB, KD |
| **Surgery** | | | Surgery |

AED, antiepileptic drug; FLB, felbamate; KD, ketogenic diet; LTG, lamotrigine; LVT, levetiracetam; MCD, Malformation of cortical development; N, No; NA, not applicable; VGB, vigabatrin; VPA, valproate; Y, Yes.
Figure 4. Interictal EEG recordings of the patients at baseline and at the end of maintenance period.
present study and our clinical experience with felbamate in ISS. The favorable safety, tolerability, and pharmacokinetic profile of radiprodil, its potential efficacy and the high unmet need warrant further studies in infants suffering from resistant seizures.

Acknowledgment

We would like to acknowledge the contribution of patients’ parents and families that participated in the study. We would also like to thank Colin Ewen for leading the project at UCB, Jean-Marie Nicholas and Miranda Cornet for their valuable contribution to the program.

Conflict of Interest

Stéphane Auvin has served as consultant or received honoraria for lectures from Advicenne Pharma, Biocodex, Eisai, GW Pharma, Novartis, Nutricia, Shire, UCB Pharma, Ultragenyx, Zogenyx. He has been investigator for clinical trials for Advicenne Pharma, Eisai, UCB Pharma and Zogenyx.

Blandine Dozières-Puyravel has received honoraria for lectures from Eisai and UCB Pharma. She has been co-investigator for clinical trials for Advicenne Pharma, Eisai, UCB Pharma and Zogenyx.

UCB biopharma was the clinical study sponsor. DS, JC, AA, RK, and PM are or were at the time this study was conducted full time employees of UCB Pharma, a pharmaceutical company active in the drug discovery, and development of new anticonvulsants.

References

1. Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the west Delphi group. Epilepsia 2004;45:1416–1428.
2. Hrachovy RA, Frost JD, Kellaway P. Hypsarrhythmia - variations on the theme. Epilepsia 1984;25:317–325.
3. McIntague A, Howell KB, Cross JH, et al. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol 2016;15:304–316.
4. Muir A, Myers C, Nguyen N, et al. Genetic heterogeneity in infantile spasms. Epilepsy Res 2019;156:106181.
5. Osborne JP, Lux AL, Edwards SW, et al. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia 2010;51:2168–2174.
6. Lagae L, Verhelst H, Ceulemans B, et al. Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study. Seizure-European. J Epilepsy 2010;19:159–164.
7. Osborne JP, Edwards SW, Alber FD, et al. The underlying etiology of infantile spasms (West syndrome): information from the International Collaborative Infantile Spasms Study (ICISS). Epilepsia 2019;60:1861–1869.
8. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013;14:383–400.
9. Ghasemi M, Schachter SC. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy Behav 2011;22:617–640.
10. Cowan LD, Hudson LS. The epidemiology and natural-history of infantile spasms. J Child Neurol 1991;6:355–364.
11. Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia 2015;56:1185–1197.
12. O’Callaghan FJK, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011;52:1359–1364.
13. Auvin S, Hartman A, Desnous B, et al. Diagnosis Delay in West syndrome: misdiagnosis and consequences. Eur J Pediatr 2012;171:1695–1701.
14. O’Callaghan FJK, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health 2018;2:715–725.
15. O’Callaghan FK, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017;16:33–42.
16. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: A prospective, randomized, blinded study. Pediatrics 1996;97:375–379.
17. Rho JA. Basic science behind the catastrophic epilepsies. Epilepsia 2004;45(s5):5–11.
18. Pierson T, Yuan H, Marsh E, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 2014;1:190–198.
19. Chachua T, Yum M-S, Veliskova J, Velisek L. Validation of the rat model of cryptogenic infantile spasms. Epilepsia 2011;52:1666–1677.
20. Velisek L, Chachua T, Yum M-S, et al. Model of cryptogenic infantile spasms after prenatal corticosteroid priming. Epilepsia 2010;51:145–149.
21. Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: evolving mechanisms. Nat Rev Neurol 2009;5:380–391.
22. Mares P, Mikulecka A. Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous
behavior, and motor performance in immature rats. Epilepsy Behav 2009;14:32–39.
23. Mares P. Age and activation determines the anticonvulsant effect of ifenprodil in rats. N-S Arch Pharmacol 2014;387:753–761.
24. Lemke JR, Geider K, Helbig KL, et al. Delineating the GRIN1 phenotypic spectrum: a distinct genetic NMDA receptor encephalopathy. Neurology 2016;86:2171–2178.
25. Platzer K, Yuan H, Schuetz H, et al. GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J Med Genet 2017;54:460–470.
26. Mullier B, Wolff C, Sands ZA, et al. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. Neuropharmacology 2017;123:322–331.
27. Sciberras D, Otoul C, Lurquin F, et al. A pharmacokinetic study of radiprodil oral suspension in healthy adults comparing conventional venous blood sampling with two microsampling techniques. Pharmacol Res Perspect 2019;7:e00459.
28. Mares P. Models of epileptic seizures in immature rats. Physiol Res 2012;61:S103–S108.
29. Dozières-Puyravel B, Nasser H, Bellavone V, et al. Felbamate for infantile spasms syndrome resistant to first-line treatments. Dev Med Child Neurol 2019; DOI:10.1111/dmcn.14427
30. Babb TL, Mikuni N, Najm I, et al. Pre- and postnatal expressions of NMDA receptors 1 and 2B subunit proteins in the normal rat cortex. Epilepsy Res 2005;64:23–30.
31. Wenzel A, Fritschy JM, Mohler H, Benke D. NMDA receptor heterogeneity during postnatal development of the rat brain: Differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 1997;68:469–478.
32. Monyer H, Burnashev N, Laurie DJ, et al. Developmental and regional expression in the rat-brain and functional-properties of 4 NMDA receptors. Neuron 1994;12:529–540.
33. Riikonen R. Update to guidelines on treatment of infantile spasms. Nat Rev Neurol 2012;8:480–482.
34. Rho JM, Donevan SD, Rogawski MA. Mechanism Of action of the anticonvulsant felbamate - opposing effects on N-methyl-D-aspartate and gamma-aminobutyric-acid, receptors. Ann Neurol 1994;35:229–234.
35. Pellock JM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res 2006;71:89–101.
36. Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. J Child Neurol 1995;10:134–136.
37. Hosain S, Nagarajan L, Carson D, et al. Felbamate for refractory infantile spasms. J Child Neurol 1997;12:466–468.